BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30662312)

  • 1.
    Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
    Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
    Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
    Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
    Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
    Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
    Parmar K; Shah J
    Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach.
    Kuk DH; Ha ES; Ha DH; Sim WY; Lee SK; Jeong JS; Kim JS; Baek IH; Park H; Choi DH; Yoo JW; Jeong SH; Hwang SJ; Kim MS
    Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3
    Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS
    Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation.
    El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H
    Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
    Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
    Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
    Sahu BP; Das MK
    Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
    Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
    Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
    Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
    Thakkar HP; Patel BV; Thakkar SP
    J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA; ElMeshad AN; Fares AR
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality by design-based optimization of formulation and process parameters for berberine nanosuspension for enhancing its dissolution rate, bioavailability, and cardioprotective activity.
    Alsabeelah N; Kumar V
    J Food Biochem; 2022 Oct; 46(10):e14361. PubMed ID: 35929374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
    Karakucuk A; Celebi N; Teksin ZS
    Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process.
    Kalvakuntla S; Deshpande M; Attari Z; Kunnatur B K
    Adv Pharm Bull; 2016 Mar; 6(1):83-90. PubMed ID: 27123422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
    Parmar K; Oza K
    AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.